TOP TEN perturbations for 1553452_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553452_at
Selected probe(set): 1553452_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553452_at (1553452_at) across 6673 perturbations tested by GENEVESTIGATOR:

psoriasis study 5 (Zaba; lesional; baseline; non-resp.) / psoriasis study 5 (Zaba; non-lesional; baseline; non-resp.)

Relative Expression (log2-ratio):1.6595764
Number of Samples:4 / 4
Experimental psoriasis study 5 (Zaba; lesional; baseline; non-resp.)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis (Zaba (Amgen) data set), classified as non-responders to etanercept treatment.
Control psoriasis study 5 (Zaba; non-lesional; baseline; non-resp.)
Non-lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis (Zaba (Amgen) data set), classified as non-responders to etanercept treatment.

atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)

Relative Expression (log2-ratio):-1.4365549
Number of Samples:20 / 18
Experimental atopic dermatitis study 12 (lesional; adults)
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (lesional; children)
Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

psoriasis study 24 (lesional; etanercept; 12wk; 50mg; non-responder) / psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)

Relative Expression (log2-ratio):-1.1370859
Number of Samples:10 / 2
Experimental psoriasis study 24 (lesional; etanercept; 12wk; 50mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 50 mg etanercept and assigned as non-responders. Etanercept was administered subcutaneously in dose of 50 mg twice weekly. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code:
Control psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 45 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 20 (lesional) / psoriasis study 20 (non-lesional)

Relative Expression (log2-ratio):1.1211038
Number of Samples:4 / 4
Experimental psoriasis study 20 (lesional)
Lesional skin punch biopsies derived from patients with chronic plaque psoriasis. 6 mm punch biopsies were obtained under local anesthesia preferentially near the central region of active plaques, except in cases where the center was poorly defined due to an irregular boundary. Regions near the edge of individual plaques were avoided to ensure that uninvolved skin was not included. Patients with one or more psoriasis plaques not limited to the scalp area were enrolled to the study. In case that only one plaque was present, a patient was admitted when that plaque occupied more than 1% of the body surface area. Patients were advised not to apply topical treatments for at least 1 week prior to biopsies and not to use systemic medications for at least 2 weeks prior to sample biopsies. Biopsies were snap-frozen in liquid nitrogen, stored at -80°C.
Control psoriasis study 20 (non-lesional)
Non-lesional skin punch biopsies derived from patients with chronic plaque psoriasis. 6 mm punch biopsies were obtained under local anesthesia from the buttocks and at least 10 cm away from the nearest active psoriasis plaque. Patients with one or more psoriasis plaques not limited to the scalp area were enrolled to the study. In case that only one plaque was present, a patient was admitted when that plaque occupied more than 1% of the body surface area. Patients were advised not to apply topical treatments for at least 1 week prior to biopsies and not to use systemic medications for at least 2 weeks prior to sample biopsies. Biopsies were snap-frozen in liquid nitrogen, stored at -80°C.

psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder) / psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder)

Relative Expression (log2-ratio):1.0723934
Number of Samples:22 / 23
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 24 (lesional; ustekinumab; 12wk; 90mg; responder) / psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder)

Relative Expression (log2-ratio):-1.0560942
Number of Samples:18 / 22
Experimental psoriasis study 24 (lesional; ustekinumab; 12wk; 90mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 90 mg ustekinumab and assigned as responders. Ustekinumab was administered subcutaneously in dose of 90 mg at week 0 and 4. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code:
Control psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 25 (lesional; baseline; ustekinumab; responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; responder)

Relative Expression (log2-ratio):1.0540829
Number of Samples:22 / 23
Experimental psoriasis study 25 (lesional; baseline; ustekinumab; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; ustekinumab; responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 25 (lesional; ustekinumab; 12wk; 90mg; responder) / psoriasis study 25 (lesional; baseline; ustekinumab; responder)

Relative Expression (log2-ratio):-1.0260859
Number of Samples:19 / 22
Experimental psoriasis study 25 (lesional; ustekinumab; 12wk; 90mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 90 mg ustekinumab and assigned as responders. Ustekinumab was administered subcutaneously in dose of 90 mg at week 0 and 4. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code:
Control psoriasis study 25 (lesional; baseline; ustekinumab; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 25 (lesional; baseline; ustekinumab; non-responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)

Relative Expression (log2-ratio):1.025218
Number of Samples:10 / 9
Experimental psoriasis study 25 (lesional; baseline; ustekinumab; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.) / psoriasis study 5 (Zaba; lesional; etanercept; 1wk; resp.)

Relative Expression (log2-ratio):-1.0073538
Number of Samples:6 / 11
Experimental psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis twelve weeks after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code:
Control psoriasis study 5 (Zaba; lesional; etanercept; 1wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis one week after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code: